Key terms

About MRNS

Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid. The company was founded in August 2003 and is headquartered in Radnor, PA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest MRNS news

Yesterday 7:50am ET Analysts Conflicted on These Healthcare Names: Cellectar Biosciences (CLRB), MiMedx Group (MDXG) and Marinus (MRNS) Mar 27 8:50am ET Marinus Comments on patent challenge by Ovid Therapeutics Mar 26 8:10am ET Analysts Offer Insights on Healthcare Companies: Precigen (PGEN), Cronos Group (CRON) and Marinus (MRNS) Mar 26 7:06am ET Marinus (MRNS) Gets a Buy from Cantor Fitzgerald Mar 26 6:16am ET Buy Rating Affirmed for Marinus Pharmaceuticals with Promising Outlook for Ganaxolone in RSE Treatment Mar 11 5:55pm ET Marinus Pharmaceuticals management to meet with Jefferies Mar 11 10:28am ET Marinus Pharmaceuticals management to meet with Jefferies Mar 07 12:45pm ET Marinus Pharmaceuticals’ ganaxolone approved by MHRA Mar 07 7:38am ET Marinus (MRNS) Receives a Hold from Oppenheimer Mar 06 11:57pm ET Buy Rating Affirmed on Marinus Pharmaceuticals Amid Strong Clinical Pipeline and Positive Trial Milestones Mar 06 11:16pm ET Marinus Pharmaceuticals Earns Buy Rating from Analyst on Strong Sales and Promising Pipeline Mar 06 8:06am ET Marinus (MRNS) Receives a Rating Update from a Top Analyst Mar 06 7:35am ET Buy Rating Affirmed: Marinus’s Promising Clinical Trials and Revenue Projections Mar 06 7:20am ET Analysts Offer Insights on Healthcare Companies: SOPHiA GENETICS (SOPH), Green Thumb Industries (OtherGTBIF) and Marinus (MRNS) Mar 06 6:46am ET Michael Higgins Endorses Marinus with a Buy Rating Amidst Promising Trials and Strong Financial Outlook Mar 06 12:30am ET Analysts Offer Insights on Healthcare Companies: Neuronetics (STIM), Marinus (MRNS) and Gritstone Oncology (GRTS) Mar 05 11:55pm ET Optimistic Buy Rating for Marinus Pharmaceuticals Based on Promising Clinical Trials and NDA Potential Mar 05 4:06pm ET Marinus Pharmaceuticals sees FY24 U.S. ZTALMY revenue $32M-$34M Mar 05 4:05pm ET Marinus Pharmaceuticals reports Q4 EPS (74c), consensus (62c) Feb 26 7:35am ET Marinus (MRNS) Receives a Buy from RBC Capital Jan 30 5:13pm ET Marinus Pharmaceuticals Stock (NASDAQ:MRNS): This Drugmaker Boasts a Rare Treatment Jan 09 1:40am ET Analysts Have Conflicting Sentiments on These Healthcare Companies: Nuvalent (NUVL), NewAmsterdam Pharma Company (NAMS) and Marinus (MRNS) Jan 05 8:46pm ET RBC Capital Sticks to Their Buy Rating for Marinus (MRNS) Jan 05 6:16am ET Marinus Pharmaceuticals: A Strong Buy on Robust Ztalmy Sales and Promising Clinical Trials Jan 04 9:45am ET Buy Rating Affirmed for Marinus Pharmaceuticals Amid Strong Q4 Sales and Promising Clinical Trials Jan 04 7:15am ET Marinus Pharmaceuticals sees FY23 U.S. ZTALMY revenue $19.5M-$19.7M

No recent news articles are available for MRNS

No recent press releases are available for MRNS

MRNS Financials

1-year income & revenue

Key terms

MRNS Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

MRNS Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms